Esomeprazole magnesium enteric-coated tablet and preparation process thereof

By using L-aspartic acid and glycerol encapsulation technology in esomeprazole magnesium enteric-coated tablets, combined with ethanol wetting and enteric coating materials, the problem of poor stability of esomeprazole magnesium in humid and high-temperature environments has been solved, achieving high drug stability and efficacy.

CN118924690APending Publication Date: 2024-11-12JINAN CENTER HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410999384.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-24
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Esomeprazole magnesium is unstable in humid and high-temperature environments, and is prone to moisture absorption, which affects the efficacy and safety of the drug.

Method used

The preparation method of esomeprazole magnesium enteric-coated tablets is adopted, which uses L-aspartic acid and glycerol to encapsulate the tablets at an appropriate pH, combined with ethanol wetting and enteric coating materials to form a protective layer that isolates air and prevents moisture absorption.

Benefits of technology

It effectively improves the stability of esomeprazole magnesium enteric-coated tablets, reduces the content of impurities, ensures that the content of the active ingredient remains basically unchanged in accelerated tests, and improves the quality and safety of the drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924690A_ABST
    Figure CN118924690A_ABST
Patent Text Reader

Abstract

The invention relates to an escomeprazole magnesium enteric-coated tablet and a preparation process thereof, and belongs to the technical field of pharmaceutical preparations for treating digestive tract or digestive system diseases, the escomeprazole magnesium enteric-coated tablet is composed of escomeprazole magnesium, L-aspartic acid, glycerin, a filler, a disintegrating agent, a lubricant and an enteric coating material, the escomeprazole magnesium is wrapped by the L-aspartic acid and the glycerol at a proper pH value, so that the escomeprazole magnesium is prevented from absorbing moisture, and the stability of the escomeprazole magnesium enteric-coated tablet is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of pharmaceutical preparations for treating digestive tract or digestive system diseases, and particularly relates to esomeprazole magnesium enteric-coated tablets and a preparation process thereof. Background Art

[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] Common diseases of the digestive system include gastric ulcer, gastroesophageal reflux disease (GERD), gastritis and duodenal ulcer, etc. These diseases usually affect food digestion and nutrient absorption, and may cause other health problems in severe cases.

[0004] Esomeprazole is a common proton pump inhibitor (PPI) used to treat gastric acid-related diseases, such as 1. Gastroesophageal reflux disease (GERD). 2. Treatment of erosive reflux esophagitis. 3. Long-term maintenance treatment to prevent recurrence in patients with cured esophagitis. 4. Combination of symptom control of gastroesophageal reflux disease (GERD) with appropriate antibacterial therapy to eradicate Helicobacter pylori. 5. Healing of duodenal ulcers associated with Helicobacter pylori infection. 6. Preventing recurrence of peptic ulcers associated with Helicobacter pylori. Its mechanism of action is: Esomeprazole inhibits H+ / K on the gastric mucosa + ATPase (proton pump), blocking the secretion of gastric acid. This drug acts on the final step of gastric acid secretion, resulting in a significant reduction in gastric acid production, which helps to alleviate the symptoms of gastric acid-related diseases and promote ulcer healing.

[0005] The Chinese patent with publication number CN111481525A discloses an omeprazole enteric-coated micro-pellet and its production process, which includes the following raw materials: omeprazole, cross-linked polyvinylpyrrolidone, mannitol, titanium dioxide, hypromellose, methacrylic acid-ethyl acrylate copolymer aqueous dispersion, synergistic stabilizer and purified water. The synergistic stabilizer is a composition of lysine, histidine, vitamin C, wolfberry polysaccharide and epicatechin, and the omeprazole enteric-coated micro-pellets are prepared by dissolving and mixing, pilling, coating with an isolation layer and coating with an enteric coating.

[0006] The Chinese patent with publication number CN114432270A discloses an omeprazole enteric-coated preparation, which comprises, from inside to outside, a drug-carrying pill core, a separation coating layer, an enteric coating layer (1), and an enteric coating layer (2). The drug-carrying pill core has a weight percentage of 25-30%, the separation coating layer has a weight percentage of 30-35%, the enteric coating layer (1) has a weight percentage of 15-25%, and the enteric coating layer (2) has a weight percentage of 15-20%. The drug-carrying pill core is composed of omeprazole, mannitol, anhydrous lactose, microcrystalline cellulose, hydroxypropyl cellulose, sodium lauryl sulfate, disodium hydrogen phosphate, and purified water; the separation coating layer is composed of hydroxypropyl methylcellulose and purified water; the enteric coating layer (1) is composed of a methacrylic acid-ethyl acrylate copolymer aqueous dispersion, triethyl citrate, talcum powder, and purified water; and the enteric coating layer (2) is composed of a methacrylic acid copolymer, triethyl citrate, talcum powder, and ethanol.

[0007] Esomeprazole is a white to slightly yellow crystalline powder. It is relatively stable when stored in dry conditions and away from light, but it is hygroscopic and its stability will be reduced in a humid and high temperature environment. Summary of the invention

[0008] The invention overcomes the defect that esomeprazole magnesium is hygroscopic and provides an esomeprazole magnesium enteric-coated tablet with high stability.

[0009] Specifically, the esomeprazole magnesium enteric-coated tablets are composed of 20 to 40 parts by weight of esomeprazole magnesium, 5 to 10 parts by weight of L-aspartic acid, 4 to 8 parts by weight of glycerol, 50 to 400 parts by weight of a filler, 3 to 20 parts by weight of a disintegrant, 1 to 5 parts by weight of a lubricant, and an enteric coating material.

[0010] It should be noted that the inventors have verified through experiments that fillers, disintegrants, lubricants, and enteric coating materials can all be selected in appropriate or pharmaceutically acceptable types and conventional amounts, which will not adversely affect the stability of the esomeprazole magnesium of the present invention.

[0011] Furthermore, the filler is selected from one or more of starch, dextrin, sucrose, lactose, microcrystalline cellulose, and mannitol; the disintegrant is selected from one or more of sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked polyvinylpyrrolidone, and cross-linked sodium carboxymethyl cellulose; the lubricant is selected from one or more of magnesium stearate, talc, micropowdered silica gel, and sodium lauryl sulfate; and the enteric coating material is Aquacoat CPD30 or ACRYLEZE.

[0012] The present invention also provides a method for preparing the esomeprazole magnesium enteric-coated tablets, comprising the following steps:

[0013] (1) Take 1 / 8 to 1 / 5 of the prescribed amount of filler and L-aspartic acid, crush them, and sieve them to obtain mixed powder 1;

[0014] (2) crushing esomeprazole magnesium, sieving, premixing with glycerin, adding a buffer solution with a pH value of 5.0 to 6.5, mixing, and then mixing with mixed powder 1 to prepare a soft material, granulating, drying, and granulating to obtain granules 1;

[0015] (3) Wetting the surface of granules 1 with ethanol, mixing with a disintegrant, drying, adding the remaining filler and lubricant, mixing, and tableting to obtain plain tablets;

[0016] (4) coating with an enteric coating material to obtain esomeprazole magnesium enteric-coated tablets.

[0017] Furthermore, the buffer solution is selected from at least one of disodium hydrogen phosphate-citric acid buffer, citric acid-sodium hydroxide-hydrochloric acid buffer, and citric acid-sodium citrate buffer. The buffer solution is selected to adjust the pH of the mixture and cooperate with the encapsulation of L-aspartic acid and glycerol to make esomeprazole magnesium reach a stable state.

[0018] Furthermore, the coating weight gain is 1.5% to 3.5%, which is a conventional coating operation in pharmacy.

[0019] Furthermore, the purpose of wetting with ethanol in step (3) is to allow the particles 1 containing esomeprazole magnesium to be coated in the disintegrant layer, which has a barrier effect on the one hand, and can help the esomeprazole magnesium enteric-coated tablets to quickly decompose in the small intestine and release the drug components on the other hand.

[0020] Compared with the prior art, the technical effects of the present invention are:

[0021] The invention uses L-aspartic acid-glycerol to wrap esomeprazole magnesium at an appropriate pH value, effectively isolates the air, prevents esomeprazole magnesium from absorbing moisture, effectively reduces the impurity content of the esomeprazole magnesium enteric-coated tablets, and improves the stability of the esomeprazole magnesium enteric-coated tablets. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 : Effect of pH on the active ingredient content of esomeprazole magnesium enteric-coated tablets in accelerated test.

[0023] Figure 2 : Effects of eight amino acids on the active ingredients of esomeprazole magnesium enteric-coated tablets in an accelerated test.

[0024] Figure 3 : Accelerated test on the changes of active ingredient content in esomeprazole magnesium enteric-coated tablets.

[0025] Figure 4: Accelerated test on the changes of total content of related substances in esomeprazole magnesium enteric-coated tablets. DETAILED DESCRIPTION

[0026] In order to make the purpose and technical solution of the present invention clearer, the present invention is further described below in conjunction with embodiments, but the protection scope of the present invention is not limited to these embodiments, and the embodiments are only used to explain the present invention. It should be understood by those skilled in the art that any changes or equivalent substitutions that do not deviate from the concept of the present invention are included in the protection scope of the present invention.

[0027] Example 1 Esomeprazole magnesium enteric-coated tablets

[0028] formula:

[0029]

[0030] Preparation method:

[0031] (1) Take 1 / 8 of the prescribed amount of filler and L-aspartic acid, crush them, and sieve them to obtain mixed powder 1;

[0032] (2) crushing esomeprazole magnesium, sieving, premixing with glycerin, adding pH=5.0 citric acid-sodium hydroxide-hydrochloric acid buffer solution to mix, and then mixing with mixed powder 1 to prepare a soft material, granulating, drying, and granulating to obtain granules 1;

[0033] (3) The surface of granules 1 is moistened with ethanol, mixed with a disintegrant, dried, and the remaining filler and lubricant are added, and tabletted to obtain plain tablets;

[0034] (4) coating with an enteric coating material to obtain esomeprazole magnesium enteric-coated tablets.

[0035] Example 2 Esomeprazole magnesium enteric-coated tablets

[0036] formula:

[0037]

[0038] Preparation method:

[0039] (1) Take 1 / 5 of the prescribed amount of filler and L-aspartic acid, crush them, and sieve them to obtain mixed powder 1;

[0040] (2) crushing esomeprazole magnesium, sieving, premixing with glycerol, adding pH=6.5 citric acid-sodium citrate buffer solution to mix, and then mixing with mixed powder 1 to prepare a soft material, granulating, drying, and granulating to obtain granules 1;

[0041] (3) The surface of granules 1 is moistened with ethanol, mixed with a disintegrant, dried, and the remaining filler and lubricant are added, and tabletted to obtain plain tablets;

[0042] (4) coating with an enteric coating material to obtain esomeprazole magnesium enteric-coated tablets.

[0043] Example 3 Esomeprazole magnesium enteric-coated tablets

[0044] formula:

[0045]

[0046]

[0047] Preparation method:

[0048] (1) Take 1 / 7 of the prescribed amount of filler and L-aspartic acid, crush them, and sieve them to obtain mixed powder 1;

[0049] (2) crushing esomeprazole magnesium, sieving, premixing with glycerol, adding disodium hydrogen phosphate-citric acid buffer solution with pH = 5.5, mixing, and then mixing with mixed powder 1 to prepare a soft material, granulating, drying, and granulating to obtain granules 1;

[0050] (3) The surface of granules 1 is moistened with ethanol, mixed with a disintegrant, dried, and the remaining filler and lubricant are added, and tabletted to obtain plain tablets;

[0051] (4) coating with an enteric coating material to obtain esomeprazole magnesium enteric-coated tablets.

[0052] Example 4 Esomeprazole magnesium enteric-coated tablets

[0053] formula:

[0054]

[0055] Preparation method:

[0056] (1) taking 1 / 6 of the prescribed amount of filler and L-aspartic acid, crushing and sieving to obtain mixed powder 1;

[0057] (2) crushing esomeprazole magnesium, sieving, premixing with glycerin, adding citric acid-sodium citrate with pH=6.0, mixing, and then mixing with mixed powder 1 to prepare a soft material, granulating, drying, and granulating to obtain granules 1;

[0058] (3) The surface of granules 1 is moistened with ethanol, mixed with a disintegrant, dried, and the remaining filler and lubricant are added, and tabletted to obtain plain tablets;

[0059] (4) coating with an enteric coating material to obtain esomeprazole magnesium enteric-coated tablets.

[0060] Example 5 Esomeprazole magnesium enteric-coated tablets

[0061] formula:

[0062]

[0063]

[0064] Preparation method:

[0065] (1) taking 1 / 6 of the prescribed amount of filler and L-aspartic acid, crushing and sieving to obtain mixed powder 1;

[0066] (2) crushing esomeprazole magnesium, sieving, premixing with glycerol, adding disodium hydrogen phosphate-citric acid buffer solution with pH = 5.8, mixing, and then mixing with mixed powder 1 to prepare a soft material, granulating, drying, and granulating to obtain granules 1;

[0067] (3) The surface of granules 1 is moistened with ethanol, mixed with a disintegrant, dried, and the remaining filler and lubricant are added, and tabletted to obtain plain tablets;

[0068] (4) coating with an enteric coating material to obtain esomeprazole magnesium enteric-coated tablets.

[0069] Comparative Example 1 Esomeprazole magnesium enteric-coated tablets

[0070] formula:

[0071]

[0072] Preparation method:

[0073] (1) taking 1 / 6 of the prescribed amount of filler and L-aspartic acid, crushing and sieving to obtain mixed powder 1;

[0074] (2) crushing esomeprazole magnesium, sieving, adding disodium hydrogen phosphate-citric acid buffer solution with pH = 5.8, mixing, and mixing with mixed powder 1 to prepare a soft material, granulating, drying, and granulating to obtain granules 1;

[0075] (3) The surface of granules 1 is moistened with ethanol, mixed with a disintegrant, dried, and the remaining filler and lubricant are added, and tabletted to obtain plain tablets;

[0076] (4) coating with an enteric coating material to obtain esomeprazole magnesium enteric-coated tablets.

[0077] Comparative Example 2 Esomeprazole magnesium enteric-coated tablets

[0078] formula:

[0079]

[0080] Preparation method:

[0081] (1) Take 1 / 6 of the prescribed amount of filler, crush it, and sieve it to obtain powder 1;

[0082] (2) crushing esomeprazole magnesium, sieving, premixing with glycerol, adding disodium hydrogen phosphate-citric acid buffer solution with pH = 5.8, mixing, and mixing with powder 1 to prepare a soft material, granulating, drying, and granulating to obtain granules 1;

[0083] (3) The surface of granules 1 is moistened with ethanol, mixed with a disintegrant, dried, and the remaining filler and lubricant are added, and tabletted to obtain plain tablets;

[0084] (4) coating with an enteric coating material to obtain esomeprazole magnesium enteric-coated tablets.

[0085] Comparative Example 3 Esomeprazole magnesium enteric-coated tablets

[0086] formula:

[0087]

[0088] Preparation method:

[0089] (1) taking 1 / 6 of the prescribed amount of filler and L-aspartic acid, crushing and sieving to obtain mixed powder 1;

[0090] (2) crushing esomeprazole magnesium, sieving, premixing with glycerin, adding an appropriate amount of purified water, mixing with mixed powder 1 to prepare a soft material, granulating, drying, and granulating to obtain granules 1;

[0091] (3) The surface of granules 1 is moistened with ethanol, mixed with a disintegrant, dried, and the remaining filler and lubricant are added, and tabletted to obtain plain tablets;

[0092] (4) coating with an enteric coating material to obtain esomeprazole magnesium enteric-coated tablets.

[0093] Comparative Example 4: Esomeprazole magnesium enteric-coated tablets

[0094] formula:

[0095]

[0096] Preparation method:

[0097] (1) taking 1 / 6 of the prescribed amount of filler and L-aspartic acid, crushing and sieving to obtain mixed powder 1;

[0098] (2) crushing esomeprazole magnesium, sieving, premixing with glycerol, adding disodium hydrogen phosphate-citric acid buffer solution with pH = 5.8, mixing, and then mixing with mixed powder 1 to prepare a soft material, granulating, drying, and granulating to obtain granules 1;

[0099] (3) Granule 1 is mixed with a disintegrant, remaining filler, and lubricant, and tabletted to obtain a plain tablet;

[0100] (4) coating with an enteric coating material to obtain esomeprazole magnesium enteric-coated tablets.

[0101] Comparative Example 5 Commercially available esomeprazole magnesium enteric-coated tablets

[0102] National Medicine Approval No. H20046379

[0103] Esomeprazole magnesium is determined according to the HPLC method (General Rule 0512) of the 2020 edition of the Chinese Pharmacopoeia. Test solution: Take 10 tablets of this product and place them in 100ml (20mg) or 200ml (40mg) volumetric bottles, add 60ml (20mg specification) or 120ml (40mg specification) of phosphate buffer (pH11.0) under identification (1), shake for 20 minutes, add 20ml (20mg) or 40ml (40mg) of ethanol, sonicate to dissolve esomeprazole, dilute to scale with the above phosphate buffer (pH11.0), shake well, filter, accurately measure 5ml of the filtrate, place it in a 25ml volumetric bottle, dilute to scale with water, and shake well. Reference solution: Take about 20 mg of omeprazole reference, accurately weigh, place in a 100 ml volumetric flask, add 20 ml of ethanol to dissolve, dilute to scale with the above phosphate buffer (pH 11.0), shake well, accurately measure 5 ml, place in a 25 ml volumetric flask, dilute to scale with water, shake well. Chromatographic conditions: Use octadecylsilane bonded silica gel as filler; acetonitrile-phosphate buffer (pH 7.3) (containing 0.0105 mol of sodium dihydrogen phosphate and 0.0300 mol of disodium hydrogen phosphate per 1000 ml)-water (35:50:15) as mobile phase; detection wavelength is 302 nm; injection volume is 20 μl. System suitability requirements: The retention time of the esomeprazole peak should be no less than 3.5 minutes, and the number of theoretical plates calculated based on the esomeprazole peak should be no less than 2000. Determination method: Accurately measure the test solution and the reference solution, inject them into the liquid chromatograph respectively, and record the chromatogram. Calculate the content of each tablet using the peak area according to the external standard method, and find the average content of 10 tablets.

[0104] The relevant substances were determined according to the HPLC method (General Rule 0512) of the 2020 edition of the Chinese Pharmacopoeia. Test solution: Take an appropriate amount of fine powder of this product (approximately equivalent to 20 mg of esomeprazole), accurately weigh it, place it in a 100 ml volumetric flask, add 10 ml of methanol, shake it, add 20 ml of phosphate buffer (pH 11.0) under Identification (1), shake it, ultrasonically dissolve esomeprazole magnesium, dilute it to the scale with water, filter it, and take the filtrate. System suitability solution: Take an appropriate amount of omeprazole and impurity I reference substance respectively, dissolve them in mobile phase A and dilute them to make a mixed solution containing approximately 0.02 mg of each in 1 ml. Chromatographic conditions: octadecylsilane bonded silica gel was used as filler (Microspher C18, 4.6 mm × 100 mm, 3 μm or a chromatographic column of equivalent performance); water-phosphate buffer (pH 7.6) (containing 0.0052 mol of sodium dihydrogen phosphate and 0.0315 mol of sodium dihydrogen phosphate per 1000 ml)-acetonitrile (80:10:10) was used as mobile phase A, acetonitrile-phosphate buffer (pH 7.6)-water (80:1:19) was used as mobile phase B, and gradient elution was performed according to Table 1; the detection wavelength was 302 nm; the injection volume was 20 μl.

[0105] Table 1 Gradient elution

[0106]

[0107] System suitability requirements: In the system suitability solution chromatogram, the retention time of the esomeprazole peak is 14-19 minutes, and the separation between the esomeprazole peak and the impurity I peak should be greater than 2.5. Determination method: Accurately measure the test solution, inject it into the liquid chromatograph, and record the chromatogram until 30 minutes. Limits: If there are impurity peaks in the chromatogram of the test solution, the impurity I content shall not exceed 0.5% by peak area normalization method, the content of other individual impurities shall not exceed 0.2%, and the total amount of impurities shall not exceed 2.0%.

[0108] Accelerated test conditions: temperature 40℃±2℃, relative humidity 75%±5%.

[0109] Effect of buffer solution pH on the stability of esomeprazole magnesium enteric-coated tablets

[0110] Based on the prescription and preparation method of Example 5, the pH in the preparation method was controlled (the type of buffer solution can be selected according to the pH), and esomeprazole magnesium enteric-coated tablets were prepared. The accelerated test was performed to determine the effect of pH on the stability of esomeprazole magnesium enteric-coated tablets.

[0111] Figure 1 To accelerate the effect of pH on the content of active ingredients in esomeprazole magnesium enteric-coated tablets, it was shown that esomeprazole magnesium is relatively stable in an acidic environment, but is more easily decomposed or loses activity in a neutral to alkaline environment.

[0112] Choice of amino acids

[0113] Amino acids can be used as protective agents, so 8 amino acids were screened to verify the protective effect on esomeprazole magnesium. Based on the prescription and preparation method of Example 5, the types of amino acids in the preparation method were changed to prepare esomeprazole magnesium enteric-coated tablets. Accelerated tests were performed to determine the effect of amino acids on the stability of esomeprazole magnesium enteric-coated tablets. Figure 2 The effects of eight amino acids on the active ingredients of esomeprazole magnesium enteric-coated tablets in accelerated tests showed that L-aspartic acid exhibited an excellent stabilizing effect, but other amino acids and L-glutamic acid, which has a similar structure, could not protect esomeprazole magnesium. It may be that L-aspartic acid can embed or bind to specific positions of the omeprazole molecule to form a protective layer or protective environment, thereby reducing the reaction of esomeprazole magnesium with other substances and prolonging the effectiveness and stability of the drug.

[0114] Stability verification of esomeprazole magnesium enteric-coated tablets

[0115] The esomeprazole magnesium enteric-coated tablets of Examples 1 to 5 and the esomeprazole magnesium enteric-coated tablets of Comparative Examples 1 to 5 were used as test samples, and their stability was verified by accelerated tests, including the content of active ingredients, the content of related substances, and the weight gain due to hygroscopicity.

[0116] Table 2 Moisture absorption and weight gain of esomeprazole magnesium enteric-coated tablets

[0117]

[0118] Esomeprazole magnesium is hygroscopic. Table 2 shows that the moisture absorption and weight gain rate of the esomeprazole magnesium enteric-coated tablets of Examples 1 to 5 of the present invention is low, which can effectively prevent esomeprazole magnesium from absorbing moisture to ensure that its quality and stability are not affected.

[0119] Figure 3 To accelerate the test of the changes in the content of active ingredients in esomeprazole magnesium enteric-coated tablets, Figure 4 In order to accelerate the test of the change in the total content of related substances in the esomeprazole magnesium enteric-coated tablets, it can be seen from the comparison that the esomeprazole magnesium enteric-coated tablets of Examples 1 to 5 of the present invention have higher stability, the content of the active ingredient remains basically unchanged in the accelerated test, the impurity content increases slowly, and the medication safety is high.

Claims

1. An esomeprazole magnesium enteric-coated tablet, It is characterized in that The esomeprazole magnesium enteric-coated tablets are composed of 20-40 parts by weight of esomeprazole magnesium, 5-10 parts by weight of L-aspartic acid, 4-8 parts by weight of glycerol, 50-400 parts by weight of a filler, 3-20 parts by weight of a disintegrant, 1-5 parts by weight of a lubricant, and an enteric coating material.

2. The esomeprazole magnesium enteric-coated tablets according to claim 1, It is characterized in that The filler is selected from one or more of starch, dextrin, sucrose, lactose, microcrystalline cellulose and mannitol.

3. The esomeprazole magnesium enteric-coated tablets according to claim 1, It is characterized in that The disintegrant is selected from one or more of sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked polyvinylpyrrolidone, and cross-linked sodium carboxymethyl cellulose.

4. The esomeprazole magnesium enteric-coated tablets according to claim 1, It is characterized in that The lubricant is selected from one or more of magnesium stearate, talc, micro powder silica gel, and sodium lauryl sulfate.

5. The esomeprazole magnesium enteric-coated tablets according to claim 1, It is characterized in that The enteric coating material is Aquacoat CPD30 or ACRYLEZE.

6. A method for preparing the esomeprazole magnesium enteric-coated tablets according to claim 1, It is characterized in that The method comprises the following steps: (1) Take 1 / 8 to 1 / 5 of the prescribed amount of filler and L-aspartic acid, crush them, and sieve them to obtain mixed powder 1; (2) crushing esomeprazole magnesium, sieving, premixing with glycerin, adding a buffer solution and mixing, and then mixing with the mixed powder 1 to prepare a soft material, granulating, drying, and granulating to obtain granules 1; (3) Wetting the surface of granules 1, mixing with a disintegrant, drying, adding the remaining filler and lubricant, mixing, and tableting to obtain plain tablets; (4) coating with an enteric coating material to obtain esomeprazole magnesium enteric-coated tablets.

7. The preparation method according to claim 6, It is characterized in that The buffer solution is selected from at least one of disodium hydrogen phosphate-citric acid buffer, citric acid-sodium hydroxide-hydrochloric acid buffer, and citric acid-sodium citrate buffer.

8. The preparation method according to claim 6, It is characterized in that The buffer solution has a pH value of 5.0 to 6.

5.

9. The preparation method according to claim 6, It is characterized in that The coating increases weight by 1.5% to 3.5%.

10. The preparation method according to claim 6, It is characterized in that In the step (3), ethanol is used for wetting.